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platelet-leukocyte aggregation after
periodontal therapy
Efthymios Arvanitidis, Sergio Bizzarro, Elena Alvarez Rodriguez, Bruno G. Loos and Elena A. Nicu*Abstract
Background: Platelets from untreated periodontitis patients are hyper-reactive and form more platelet-leukocyte
complexes compared to cells from individuals without periodontitis. It is not known whether the improvement of
the periodontal condition achievable by therapy has beneficial effects on the platelet function. We aimed to
assess the effects of periodontal therapy on platelet reactivity.
Methods: Patients with periodontitis (n = 25) but unaffected by any other medical condition or medication were
included and donated blood before and after periodontal therapy. Reactivity to ADP or oral bacteria was assessed
by flow cytometric analysis of membrane markers (binding of PAC-1, P-selectin, CD63) and platelet-leukocyte
complex formation. Reactivity values were expressed as ratio between the stimulated and unstimulated sample.
Plasma levels of soluble (s) P-selectin were determined by enzyme-linked immunosorbent assay (ELISA).
Results: Binding of PAC-1, the expression of P-selectin and CD63 in response to the oral bacterium P. gingivalis
were lower at recall (1.4 ± 1.1, 1.5 ± 1.2, and 1.0 ± 0.1) than at baseline (2.7 ± 4.1, P = 0.026, 6.0 ± 12.5, P = 0.045, and
2.7 ± 6.7, P = 0.042, respectively). Formation of platelet-leukocyte complexes in response to P. gingivalis was also
reduced at recall compared to baseline (1.2 ± 0.7 vs. 11.4 ± 50.5, P = 0.045). sP-selectin levels were significantly
increased post-therapy.
Conclusions: In periodontitis patients, the improvement of the periodontal condition is paralleled by a reduction
in platelet hyper-reactivity. We suggest that periodontal therapy, as an intervention for improved oral health, can
facilitate the management of thrombotic risk, and on the long term can contribute to the prevention of
cardiovascular events in patients at risk.
Trial registration: Current Controlled Trials identifier ISRCTN36043780. Retrospectively registered 25 September 2013.
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ComplexesBackground
Periodontitis is a chronic inflammatory disease of the
teeth-supporting tissues characterized by progressive loss
of attachment, deepening and ulceration of the barrier
epithelium [1]. Under these circumstances, bacteremia
with oral microorganisms is a common phenomenon
during everyday activities, such as chewing and tooth
brushing [2]. Oral bacterial species (among them* Correspondence: e.nicu@acta.nl
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been identified in atherosclerotic plaques [3] and are in-
volved in the pathogenesis of infective endocarditis [4].
Mechanisms of action include the capacity of oral bacteria
to activate platelets [5, 6] and the formation of platelet-
leukocyte complexes, containing activated platelets and
leukocytes [7, 8].
Although periodontitis is a common condition (47% of
U.S. dentate adults aged 30 years and older [9]) associ-
ated with chronic low-grade inflammatory state and ath-
erosclerotic vascular disease [10], it is only sparsely
investigated as a potential source of ongoing plateletle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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that platelets are more activated in periodontitis patients
[11]. Besides the more activated state, the platelets and
their complexes with leukocytes are hyper-reactive in re-
sponse to ADP and oral bacteria [12].
It is not known whether periodontal therapy could
affect platelet hyper-reactivity thereby facilitating a
better management of the cardiovascular risk. We
hypothesized that circulating platelets and platelet-
leukocyte complexes from peripheral blood of periodon-
titis patients become less reactive upon stimulation after
the provision of non-surgical periodontal therapy.
Therefore, the aim of this study was to investigate the
effect of non-surgical periodontal therapy on platelet
reactivity. To this end, we analyzed platelet membrane-
bound activation markers expression and the formation
of platelet-leukocyte complexes in response to ADP
and oral bacteria (Aggregatibacter actinomycetemcomi-
tans [Aa], Porphyromonas gingivalis [Pg], Tannerella




All chemicals were purchased from Sigma Chemical (St
Louis, MO, USA). The HEPES buffer solution consisted
of 137 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 5.6 mM
glucose, 20 mM HEPES, 1 mg/mL bovine serum albu-
min, 3.3 mM NaH2PO4, pH 7.4. The lysing solution
contained 155 mM NH4Cl, 10 mM KHCO3, 0.1 mM
EDTA, pH 7.4 and was stored at 4 °C. The antibodies
against surface markers were: CD4-PE, CD14-PE, CD45-
APC, CD61-PerCP, CD62P-PE, CD62P-FITC, CD63-PE,
CD66b-FITC, PAC-1 FITC, and their isotype control
antibodies (all from BD Pharmingen, San Jose, CA,
USA). CD61-APC was from Dako (Glostrup, Denmark).
Bacterial strains and culture conditions
For this experiment, Aa, Pg, Tf, Ss and Sm were grown
as described in a previous study [12]. The bacterial
suspensions were washed by centrifugation, reduced to
an optical density of 1 at 600 nm in HEPES-buffer and
stored in aliquots at −20 °C.
Patient selection and study protocol
The study population is part of a cohort of moderate-to-
severe adult periodontitis patients participating in a
clinical trial in the Department of Periodontology at the
Academic Centre for Dentistry of Amsterdam (the
Netherlands) [13]. Within a period of eighteen months
(February 2012-September 2013), all consecutive patients
fulfilling the inclusion criteria were included in this study.
Patients were recruited if they fulfilled the following inclu-
sion criteria: presence of chronic periodontitis, self–reported good general health and not being aware of any
form of diabetes, cardiovascular disease, (auto) immune
disease or any other systemic or metabolic disease, and
not receiving any medication for hypertension, dyslipid-
emia of hyperglycemia. Further exclusion criteria were:
regular use of medications that could influence platelet
function (i.e. NSAIDs, acetylsalicylic acid, dipyridamole,
thienopyridines), use of antibiotics in the past 6 months,
periodontal treatment in the last 2 years, pregnancy or lac-
tation, presence of implants or orthodontic appliances and
presence of <20 natural teeth.
Participants were scheduled for two sessions of non-
surgical periodontal therapy (average duration of 5 h)
under local anesthesia conducted by two experienced
staff oral hygienists. All subjects received a demonstra-
tion of basic oral hygiene principles with an electric
toothbrush (Philips Sonicare®, Bothell, WA, USA) and
were instructed to use interdental means of cleaning
followed by rinsing with chlorhexidine 0.12% twice daily.
The patients were recalled at six weeks for reinforcement
of oral hygiene and localized rescaling of bleeding pockets.
Patients were subsequently enrolled in a 3-monthly main-
tenance program. At baseline and recall (3 months after
treatment) blood samples were taken into 0.32% citrate
vacuum tubes (BD Vacutainer blood collection tube,
Becton Dickinson, Oxford, UK). Citrated plasma was pre-
pared by centrifugation (2000 g, 4 °C, 10 min). Aliquots
were stored at −80 °C.
Platelet reactivity
At baseline and the 3 months-recall (twelve weeks after
completion of active periodontal therapy), fasting blood
samples for platelet assays were collected between
08:00–10:00 a.m. by venipuncture of the antecubital
fossa (0.32% sodium citrate containing blood collection
tubes). Blood was kept at room temperature and proc-
essed within 30 min of collection.
Aliquots of whole blood (10 μL) were diluted in 30 μL
of HEPES-buffer (unstimulated control) or incubated
with bacterial suspensions of Aa, Pg, Tf, Ss and Sm.
Adenosine diphosphate (ADP, 10 μM) was used as a
positive control [14]. The reaction vials contained APC-
labeled anti-CD61, FITC-labeled PAC-1 plus PE-labeled
anti-CD62P or APC-labeled anti-CD61 plus PE-labeled
anti-CD63 (4 μg/mL, final concentration) [15]. To set
fluorescence thresholds, 4 μg/mL PE-IgG1 and 4 μg/mL
FITC-IgM isotype control antibodies were used. The
mixes were allowed to incubate for 30 min at room
temperature in the dark. The samples were fixed by
adding HEPES-buffer containing 0.3% paraformaldehyde
(PFA, 2.5 mL). Whole blood flow cytometry was con-
ducted on Accuri™ flow cytometer employing C6 soft-
ware (Becton Dickinson, Michigan, USA). Forward (size)
and side (granularity) scatter were set at logarithmic gain
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recorded. Platelets were identified on basis of a character-
istic forward and side scatter and specific binding of
CD61. Within the platelet gate, fluorescence was employed
to distinguish between PAC-1, CD62P or CD63 positive
cells. Exposure of platelet activation markers was de-
termined on 2500 platelets. The threshold for platelet
activation was set at 1% of the appropriate isotype
control-antibody.
Platelet-leukocyte complexes
For the platelet-leukocytes essays, fresh citrated blood
(20 μL) was incubated with or without stimulants (see
Platelet Reactivity), at room temperature in the dark. Leu-
kocytes were identified using the 90°-light scatter and the
expression of CD45 (Fig. 1a). Within each subpopulation
gate (neutrophils, monocytes, lymphocytes), the expres-
sion of CD61 was determined (Fig.1b-g). The identity of
neutrophils, monocytes, and lymphocytes was confirmed
by the characteristic expression of CD66b, CD14 and CD4,
respectively. The threshold for platelet-leukocyte binding
was set at 1% using an isotype control antibody corre-
sponding to the non-specific binding; above this threshold
all leukocytes were considered to be CD61 positive reflect-
ing the platelet-leukocyte complexes. After a 15 min incu-
bation, 500 μL of cold (4 °C) lysing solution was added and
each sample was placed on ice. Upon lysis, fixation was
achieved with the addition of 0.3% PFA solution.Fig. 1 Flow cytometric features of leukocytes, neutrophils, monocytes, and
events. The Neutrophils gate is characterized by high side scatter and low
side scatter and intermediate CD45 expression, and the Lymphocyte gate i
events within the Neutrophils gate in a were represented in a CD66b and
CD61 designate the platelet-neutrophil complexes (PNCs, dotted box in b.
platelet-monocyte complexes, PMCs, are in the dotted box in c and lymph
the dotted box in d. An example of an unstimulated sample (incubated in
of a stimulated sample (incubated in ADP) is shown in e, f, and gSoluble P-selectin determination
The concentration of circulating P-selectin in plasma
was measured with a commercial enzyme-linked im-
munosorbent assay (sP-Selectin/CD62p ELISA kit, R&D
Systems Inc., Minneapolis, MN, USA). The measure-
ments were performed following the manufacturer’s
instructions. For sP-selectin determination, plasma sam-
ples were diluted 20 fold. The diluted plasma specimens
were added together with an anti-sP-selectin antibody
conjugated to peroxidase into a 96-well plate precoated
with another anti-sP-selectin monoclonal antibody
(MAb) and incubated for 1 h. Substrate was then added,
and absorbance values were measured at 450 nm with a
plate reader (Synergy HT, BioTek, Winooski, VT, USA).
The concentration of each sample was determined by
extrapolation from a standard curve estimated from a
panel of sP-selectin standards of known concentrations
and corrected for the dilution effect of the liquid anti-
coagulant (citrate). Plasma levels of sP-selectin were
expressed as ng/mL. The intra-assay and inter-assay co-
efficients of variance were 5.2% and 8.7%, respectively.
Statistical analysis
Our sample size calculation was based on the observed
mean ± SD of the fold increase in P-selectin (CD62p)
expression on platelets after bacterial stimulation as re-
ported by Nicu et al. [12]. We calculated that we needed
to include 29 patients to be able to detect a reduction inlymphocytes and their complexes with platelets. Panel a is showing all
CD45 expression, the Monocytes gate is characterized by intermediate
s characterized by low side scatter and high CD45 expression. All
CD61 plot. Events characterized by high expression of both CD66b and
Similar strategy was employed for the monocytes (using CD14, the
ocytes (using CD4, the platelet-lymphocyte complexes, PLymCs, are in
HEPES buffer) is shown in b, c, and d, whereas flow cytometric analysis
Arvanitidis et al. Thrombosis Journal  (2017) 15:5 Page 4 of 10platelet reactivity after periodontal therapy with a power
of 85% (using a two-sided alpha level of 0.05).
Statistical analysis was performed using SPSS software
(v.20.0; IBM, Chicago, Illinois, USA). GraphPad Prism (v.
6.0; GraphPad Software, San Diego, California, USA) was
used for the graphic representation of all data. Normality
of the data distribution was assessed by Kolmogorov-
Smirnov test. When using parametric testing, the data sets
showing a non-normal distribution were log-transformed
before statistical analysis. The anthropometric, biochem-
ical and clinical characteristics at baseline and recall were
compared using the paired t-test.
Platelet reactivity was expressed as the ratio between
the mean fluorescent intensity (MFI) of the indicated
activation marker after stimulation and the MFI of the
same marker in the absence of stimulation (cells in
HEPES-buffer). The number of CD61-positive (equiva-
lent to platelet-conjugated) leukocytes, neutrophils,
monocytes and lymphocytes was recorded as a percent-
age of the total population of each respectively. Ratios were
calculated [% platelet-bound cells after stimulation/%
platelet-bound cells in HEPES-buffer] representing the
change in number of complexes formed in response to
stimulation with oral bacteria or ADP. A general linear
model (repeated measures ANOVA using the Huyhn-Feldt
correction followed by Bonferroni correction for multiple
comparisons), was applied. In this model, comparisons be-
tween stimulated (ADP, Aa, Pg, Tf, Ss, Sm) and unstimu-
lated samples (Hepes) were acquired (within timepoint
comparisons, at baseline and recall). Secondly, between
timepoints (baseline and recall) comparisons for each
stimulus were assessed by applying the paired t-test. P-
values < 0.05 were considered statistically significant.
The fold changes over time in PAC-1, CD62p, CD63,
platelet-leukocyte, platelet-neutrophil or platelet-monocyte
complexes, LDL levels, systolic blood pressure, waist cir-
cumference, number of periodontal pockets deeper than
6 mm were calculated by dividing the value of each param-
eter at recall by its value at baseline. The fold changes over
time in PAC-1 (in response to ADP, Pg, Sm), CD62p (Pg),
CD63 (Pg), platelet-leukocyte (Pg), platelet-neutrophil (Tf,
Ss) or platelet-monocyte complexes (Ss) were entered as
dependent variables, and the amount of smoking (pack-
years), change in LDL levels, change in systolic blood pres-
sure, change in waist circumference, change in number of
periodontal pockets deeper than 6 mm as predictors.
Multiple linear regression (Enter method) was used to
model the relationship between the calculated platelet-
related parameters and these predictors.
Results
Patient characteristics and effect of treatment
Within the study period thirty consecutive patients were
included in this study; however, due to schedulingconflicts (regarding blood collection and processing), only
25 data sets were available as a complete set (baseline and
recall at 12 weeks post-therapy). Demographic and dental
characteristics of the participants are described in Table 1.
The prevalence of chronic smokers (>10 years) within this
group was high (56%). Interestingly, six patients success-
fully quitted smoking within the duration of the study.
Two subjects were classified as obese (BMI > 30 kg/m2,
waist circumference > 124 cm), while hypercholesterol-
emia (total cholesterol > 6.2 mmol/L) was noted for three
subjects. Using the biochemistry results (summarized in
Table 1) we gave the patients a composite score of meta-
bolic syndrome at baseline, according to the presence of
central obesity (WC ≥102 cm in men or ≥88 cm in
women) together with ≥2 of the following risk determi-
nants: triglycerides ≥1.7 mmol/l, HDL <1.03 mmol/l in
males or <1.29 mmol/l in females, blood pressure ≥130/
85 mmHg, fasting glucose ≥5.6 mmol/l [16]. Based on
this composite score, only 3 out of the 25 participants
scored as having metabolic syndrome. LDL levels were
lower at recall compared to baseline (P = 0.03). Further,
seven patients received systemic antimicrobials (375 mg
amoxicillin and 250 mg metronidazole, t.i.d, 7 days) as
an adjunct to non-surgical periodontal therapy. The
leukocyte and platelet counts were comparable before
and after periodontal therapy (P = 0.852 and 0.570,
respectively). As expected, the treatment resulted in sig-
nificant improvement in all clinical periodontal variables
(P < 0.001, Table 1). Four teeth were extracted in total,
three of them in one individual.
Platelet reactivity
To determine the reactivity of circulating platelets, P-
selectin and CD63 expression, and PAC-1 binding in re-
sponse to stimulation was assessed (Fig. 2). Stimulation
with ADP led to a significant many-fold increase in
platelet activation over the unstimulated sample (Fig. 2a,
b, c). Similarly, co-incubation of whole blood with oral
bacteria induced a smaller but significant amount of
platelet activation (overall P < 0.001 for the within time-
point analysis for all three markers). More specifically,
Ss was the strongest inducer of platelet activation (post
hoc P < 0.05 for all three markers). The PAC-1 binding
was lower at recall than at baseline in response to stimu-
lation with ADP (mean ratio MFIrecall = 14.3 vs. mean
ratio MFIbaseline = 21.6, P = 0.042), Pg (mean ratio MFIre-
call = 1.4 vs. mean ratio MFIbaseline = 2.7, P = 0.026) and
Sm (mean ratio MFIrecall = 2.9 vs. mean ratio MFIbaseline
= 3.9, P = 0.017, Fig. 2a). A non-significant reduction in
PAC-1 binding was measured at recall in response to Aa
and Ss. The P-selectin expression in response to Pg was
lower at recall than baseline (mean ratio MFIrecall = 1.6
vs. mean ratio MFIbaseline = 6.0, P = 0.045, Fig. 2b). Simi-
larly, CD63 expression after Pg stimulation was lower at
Table 1 Summary of the study population characteristics (n = 25) at baseline and recall (12 weeks post-therapy)
Baseline Recall P-value
Age 44.7 ± 9.3 - -
Gender (male/female) 11/14 - -
Ethnicity (Caucasian/non-Caucasian) 21/4 - -
Smoking (current/former/never) 14/5/6 8/11/6 -
Packyears 16.5 ± 13.8 - -
BMI (kg/m2) 25.0 ± 5.1 25.3 ± 5.2 NS
Waist circumference (cm) 95.6 ± 17.2 94.8 ± 16.9 NS
Blood pressure (mm Hg)
Systolic 124.8 ± 19.4 127.2 ± 16.1 NS
Diastolic 76.1 ± 13.4 77.2 ± 11.9 NS
Total cholesterol (mmol/L) 5.2 ± 0.8 4.9 ± 0.9 NS
HDL (mmol/L) 1.5 ± 0.4 1.4 ± 0.5 NS
LDL (mmol/L) 3.2 ± 0.8 2.8 ± 0.7 P = 0.03
Triglycerides (mmol/L) 1.2 ± 1.0 1.4 ± 1.1 NS
C-reactive protein (mg/L) 2.1 ± 2.8 2.0 ± 3.9 NS
Fibrinogen (g/L) 2.9 ± 0.6 2.8 ± 0.6 NS
Leukocyte counts (× 109/L) 6.7 ± 2.0 6.6 ± 2.2 NS
Neutrophils 3.9 ± 1.6 3.8 ± 1.9 NS
Lymphocyte counts 2.0 ± 0.6 2.2 ± 1.1 NS
Platelet counts (× 103) 250.4 ± 66.1 246.6 ± 56.6 NS
Number of teeth 27.6 ± 2.6 27.4 ± 2.6 NS
#teeth with > 50% bone loss 4.4 ± 3.1 4.1 ± 3.1 NS
Sites with plaque (%) 74.6 ± 20.0 19.0 ± 13.0 P < 0.001
Sites with bleeding on probing 65.9 ± 15.0 18.7 ± 9.1 P < 0.001
Probing Pocket Depth (mm) 4.0 ± 0.6 2.9 ± 0.4 P < 0.001
Pockets≥ 5 mm (%) 32.4 ± 14.5 11.7 ± 9.0 P < 0.001
Clinical Attachment Level (mm) 4.3 ± 0.9 3.6 ± 0.8 P < 0.001
Values are presented as means ± standard deviations or number of subjects
BMI (body mass index), HDL (high density lipoproteins), LDL (low density lipoproteins)
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vs. mean ratio MFIbaseline = 2.7, P = 0.042, Fig. 2c).
Formation of platelet-leukocyte complexes
Incubation of fresh platelets with ADP or oral bacteria
resulted in formation of platelet-leukocyte complexes
(PLC) both at baseline and recall (overall P < 0.001 for
the within timepoints analysis, Fig. 3). Specifically,
formation of platelet-neutrophil (PNC) and platelet-
monocyte complexes (PMC) was significantly induced
by stimulation (Table 2). The strongest inducers of PLC,
PNC or PMC were ADP, Tf and Ss (post-hoc P < 0.05).
Formation of platelets-lymphocyte complexes (PLymC)
appeared less influenced either by ADP or oral bacteria
(Table 2, P > 0.05).
Less PLC formation could be observed at recall
compared to baseline in response to Pg (mean ratio%PLCrecall = 1.2 vs. mean ratio %PLCbaseline = 11.4, P =
0.045, Fig. 3). Furthermore, less PNC were formed at recall
compared to baseline in response to Tf (P = 0.045) and Ss
(P = 0.009, Table 2). Similarly, less PMCs were formed at
recall in response to Tf (P = 0.065), Ss (P = 0.004), and Sm
(P = 0.093). PLymC formation was unaffected by time or
bacterial stimulation (P > 0.05, Table 2).
The intrinsic platelet activation status at recall com-
pared to baseline is presented in Additional file 1, in
which raw data of the unstimulated condition (sam-
ples incubated in HEPES buffer) are summarized.
None of the tested parameters were significantly dif-
ferent between baseline and recall. We noted a trend
towards higher PAC-1 binding 3 months post-treatment
(P = 0.061) and higher percentage of platelet-neutrophils
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Fig. 2 Platelet response to stimulation with ADP or oral bacteria
(Aggregatibacter actinomycetemcomitans [Aa], Porphyromonas
gingivalis [Pg], Tannerella forsythia [Tf], Streptococcus sanguis [Ss] and
Streptococcus mutans [Sm]). The mean fluorescence intensity (MFI) of
(a) PAC-1 binding, (b) P-selectin (CD62P) and (c) CD63 in response
to an agonist was recorded as a measure of reactivity. The data were
plotted as fold change in MFI [MFI of individual sample after stimulation/
MFI of unstimulated sample in buffer] representing the change in
reactivity. Data are presented as means ± standard error of the mean
(N= 25). Addition of stimuli induced an increase in platelet surface
activation markers when analyzed within each timepoint (P< 0.001 -
repeated measures ANOVA). The comparisons between timepoints were























Fig. 3 Formation of platelet-leukocyte complexes in response to stimu-
lation with ADP or oral bacteria (Aggregatibacter actinomycetemcomitans
[Aa], Porphyromonas gingivalis [Pg], Tannerella forsythia [Tf], Streptococcus
sanguis [Ss] and Streptococcus mutans [Sm]). The number of CD61-
positive (equivalent to platelet-conjugated) leukocytes (PLC) was
recorded as a percentage of the total population. Data were plotted as
fold change [% platelet-bound cells after stimulation/% platelet-bound
cells in unstimulated sample in buffer] representing the change in
number of complexes formed in response to stimulation with ADP or oral
bacteria. Data are presented as means ± standard error of the mean
(N= 25). The addition of stimuli induced formation of complexes when
analyzed within each timepoint (P < 0.001 in repeated measures
ANOVA). The comparisons between timepoints were analyzed by
paired T- test (*P < 0.05 baseline vs. recall)
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At baseline, sP-selectin values ranged between 15.8 ng/mL
and 72.8 ng/mL (mean ± standard deviation 40.5 ± 15.1 ng/
mL, Fig. 4). The plasma levels of sP-selectin at recall (range
21.1 - 123.8 ng/mL, mean ± SD: 56.4 ± 22.8 ng/mL) were
significantly increased compared to baseline (P = 0.0008).
The plasma concentration of sP-selectin was not
correlated with the platelet expression of P-selectin
(CD62p expression in unstimulated samples) at base-
line (R = −0.37, P = 0.863) or recall (R = 0.006, P =
0.979).
Linear regression models
Linear regression analyses were run for all the platelet pa-
rameters showing a significant decrease post-treatment
(PAC-1 binding in response to ADP, Pg, and Sm, CD62
response to Pg, CD63 response to Pg, PLC formation in
response to Pg, PNC formation in response to Tf, PNC
formation in response to Ss, PMC formation in response
to Ss). The regression models included the following vari-
ables as predictors: smoking amounts, LDL (ratio recall/
baseline), waist circumference (ratio recall/baseline),
systolic blood pressure (ratio recall/baseline) and the clin-
ical response to periodontal treatment (ratio between the
number of periodontal pockets deeper than 6 mm at re-
call/baseline). The results of these regression models are
presented in Additional file 2. The final regression
Table 2 Summary of platelet-neutrophil, platelet-monocyte and platelet-lymphocyte complexes formation in response to
stimulation






Baseline Recall P-value Baseline Recall P-value Baseline Recall P-value
+ADP 6.9 ± 7.9 8.6 ± 19.3 0.468 +ADP 13.0 ± 19.4 8.4 ± 16.8 0.339 +ADP 4.7 ± 8.1 7.1 ± 10.5 0.072
+Aa 2.1 ± 1.8 6.1 ± 17.5 0.766 +Aa 2.7 ± 2.5 1.9 ± 1.3 0.265 +Aa 7.7 ± 19.2 3.9 ± 8.2 0.483
+Pg 9.4 ± 40.1 2.4 ± 5.6 0.462 +Pg 2.1 ± 3.2 1.2 ± 1.0 0.100 +Pg 1.8 ± 2.1 2.0 ± 3.0 0.535
+Tf 32.9 ± 56.2 14.9 ± 30.5 0.028 +Tf 8.7 ± 8.3 7.7 ± 19.6 0.072 +Tf 11.5 ± 23.2 9.3 ± 12.1 0.431
+Ss 51.3 ± 93.4 15.4 ± 31.9 0.003 +Ss 13.2 ± 20.1 7.0 ± 25.1 0.004 +Ss 4.1 ± 10.6 3.9 ± 5.9 0.529
+Sm 1.4 ± 1.4 2.7 ± 7.8 0.906 +Sm 2.2 ± 2.0 1.2 ± 1.2 0.046 +Sm 1.4 ± 0.8 2.7 ± 3.8 0.087
Values are presented as means ± standard deviations. The platelet-neutrophil complexes, platelet-monocyte complexes, platelet-lymphocyte complexes were
calculated as percentages platelet-positive neutrophils, monocytes or lymphocytes from the total number of neutrophils, monocytes or lymphocytes, respectively.
The fold change over unstimulated values represent the ratios between the measured values after stimulation with ADP, Aa, Pg, Tf, Ss or Sm and in the absence
of stimulation (cells in buffer). P-values were obtained by paired T-test and the significant values are given in bold
ADP (adenosine diphosphate), Aa (Aggregatibacter actinomycetemcomitans), Pg (Porphyromonas gingivalis), Tf (Tannerella forsythia), Ss (Streptococcus sanguis),
Sm (Streptococcus mutans)
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yielded R2: 0.584, F = 3.083; P = 0.05. From this regression
model it became apparent that the clinical response to
periodontal treatment positively predicted the improve-
ment in PAC-1 binding in response to ADP (B = 3.26, t =
2.76, P = 0.02) and Sm (B = 2.41, t = 2.29, P = 0.04). The
positive relation between PAC-1 binding and response to
treatment translates into: the reduction in the number of
periodontal pockets deeper than 6 mm after treatment is
positively correlated with the reduction in PAC-1 binding
in response to ADP or Sm.
None of the other variables included in the models
predicted the change in platelet parameters (P > 0.05).
Discussion
Many inflammatory states, e.g. systemic lupus erythema-
tosus, pneumonia, or inflammatory bowel disease featureFig. 4 Concentration of sP-selectin (N = 24) in citrate plasma at baseline
(white bars) and recall (black bars). Data are presented as means ±
standard deviation. P-value calculated by paired t- test (***P = 0.0008)increased platelet reactivity, and potentially hypercoagu-
lability with an increased risk for cardiovascular events
[17–20]. Periodontitis is a condition characterized by
low-grade inflammatory and infectious burden with
systemic distribution of pro-inflammatory cytokines or
bacterial products. We have previously documented
hyper-reactivity of platelets in response to ADP and oral
bacteria in untreated periodontitis patients as compared
to matched controls [12]. In the current study we show
that the improvement in the periodontal condition after
non-surgical periodontal therapy is accompanied by a
significant reduction in platelet reactivity, as reflected by
lower PAC-1 binding, lower P-selectin expression and
lower induction of platelet-leukocyte complexes in re-
sponse to an agonist.
The circulation of leukocytes across the vascular endo-
thelium is required for immune surveillance and for
leukocyte recruitment at inflammatory sites. Platelet bind-
ing alters the adhesive and migratory phenotype of leuko-
cytes, with platelet-monocyte and platelet-neutrophil
complexes being more adhesive, thus resulting in en-
hanced transmigration through vascular endothelium [21].
Conversely, when the periodontal inflammatory lesions
heal after periodontal therapy, the need for recruitment of
inflammatory cells will decrease. This could explain our
finding of reduced propensity to form platelet-leukocyte
complexes after periodontal treatment. A positive side ef-
fect of this therapy could result in a reduced participation
of platelets and leukocytes to the progression of athero-
thrombosis [22–24], potentially benefitting the patients at
cardiovascular risk.
It has been reported in (systematic) reviews that suc-
cessful treatment of periodontitis is accompanied by a
decrease in systemic markers of inflammation such as
CRP or leukocyte counts [25, 26]. In our study the CRP
levels and leukocyte counts did not change after peri-
odontal therapy. However, this finding must be
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we have applied. In this work, patients with any known
co-morbidities were excluded. Although inclusion in the
study was based on the self-reported health status, which
might underestimate the prevalence of a medical condi-
tion when compared to diagnosis based on laboratory
data [17], we have strong indications that the large ma-
jority of our participants were healthy, as only 3 out of
25 fulfilled the criteria for metabolic syndrome [16]. In
the most recent meta-analysis of the effects of peri-
odontal treatment on CRP levels, Teeuw and co-
workers analyzed and presented separately the results
from subjects with periodontitis, but otherwise healthy
(without co-morbidities) and those from subjects with co-
morbidities. From their meta-analysis it was concluded
that it is the patients with co-morbidities that benefit the
most from periodontal therapy, showing consistent reduc-
tion in CRP levels after treatment, whereas in the group
without co-morbidities the change in CRP levels over time
after periodontal treatment was not different than in the
untreated control group [27]. An explanation for this find-
ing might be the low baseline CRP values in most of the
participants in our study (only 3 patients had CRP above
the high risk AHA threshold of 3.0 mg/L). Ridker and co-
workers reported a significant reduction in the risk for
myocardial infarction after aspirin administration in the
highest quartile of baseline CRP levels, but not in the low-
est quartile [28]. The authors concluded that a certain
inflammatory threshold might be necessary before anti-
infective/inflammatory treatments can deliver measurable
effects, and we suggest that this is the mechanism behind
the non-significant change in inflammatory markers in
our study population after periodontal treatment.
Interestingly, in the current study, the LDL levels were
reduced after periodontal therapy. Our results are in line
with previous reports of improved serum lipid levels
post periodontal therapy in patients with periodontitis,
but otherwise healthy, in the absence of any adjunctive
lipid-lowering intervention (dietary advice or pharmaco-
logical cholesterol reduction medication) [29, 30]. Simi-
lar to the effects that periodontal therapy has on CRP
levels, the lipid profiles show greater improvement in
periodontitis patients with co-morbidities, e.g. hyperlip-
idemia, diabetes [31–33].
P-selectin is expressed on the cell surface of platelets
and endothelial cells after activation [34], and mediates
leukocyte adhesion to these activated cell types. We
found a statistically significant, albeit modest, increase
3 months after periodontal therapy of sP-selectin levels.
A similar trend post-treatment was observed by
Marcaccini et al. [35]. Interestingly, also the unstimu-
lated platelet activation values, representing intrinsic
activity, showed a trend of slight increase (Additional
file 1). It would be interesting to see in future studieslonger term results (more than 6 months) for these pa-
rameters. Activated platelets rapidly shed their
membrane-bound P-selectin, which subsequently can
be found as circulating sP-selectin [36], while platelets
remain functional and responsive to stimulation.
Possibly, this latter phenomenon explains why in peri-
odontitis patients we found increased sP-selectin post-
therapy, while their platelet reactivity was reduced.
However, the increased sP-selectin post-therapy might
be a marker of early endothelial function recovery.
Previous observations have shown that in vivo, the
adhesiveness of the endothelium is controlled by
shedding of P-selectin [37]. Moreover, the shed soluble
P-selectin is likely to inhibit additional leukocyte adhe-
sion and may have a “calming” effect on the recruited
neutrophils [38], which again may be part of the healing
processes initiated post-therapy. Indeed, periodontal
therapy has been shown to improve endothelial
dysfunction [39], and our results provide insights into
the cellular players involved.
Although slightly increased post-treatment, the sP-
selectin levels in our periodontitis patients were lower
than previously reported for both untreated periodontitis
or healthy (periodontally unaffected) controls [11, 35].
We are cautious in interpreting these results, mainly be-
cause in the current study we measured sP-selectin in
citrate plasma, and not in EDTA-plasma, like in the
studies by Marcaccini et al. and Papapanagiotou et al. It
has been shown that sP-selectin is lower in citrate than
in EDTA [40], rendering comparisons between studies
employing different anticoagulants highly hazardous.
The most widely used methods for the analysis of
platelet function in vitro include global tests for whole
blood such as the Platelet Function Analyzer 100 (PFA-
100®), Plateletworks®, VerifyNow® or thromboelastogra-
phy and specific tests such as the light transmission
aggregometry (LTA), the flow cytometry-based tests or
the ELISA-based tests [41]. Global tests are useful in
monitoring the individual on-treatment platelet reactiv-
ity in clinical settings [42], however, they lack sensitivity
and specificity due to interplay with multiple non-
platelet related factors, e.g. plasma-derived adhesion and
(anti)-coagulation factors, red blood cells and leukocytes
[41]. LTA, on the other hand, enables the analysis of dis-
tinct activation mechanisms on isolated platelets (plate-
let-rich plasma or plasma-depleted platelet preparations)
and represents the “gold standard” of platelet function
analysis in vitro. However, LTA lacks the attributes
needed for a point-of-care test: it requires sample prep-
aration, is time consuming, operator-sensitive and has
limited recommendation for monitoring anti-platelet
therapy responses [41].
The methods employed in the current study, i.e. the
flow cytometric evaluation of platelet surface markers and
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plasma by ELISA are both of a static nature. Ideally, plate-
let functions should be assessed under flow conditions,
since some biologically relevant interactions such as that
of GP1bα and VWF are relevant under shear stress. The
hospital based analyzers such as the PFA-100® and Verify-
Now® incorporate some aspect of shear stress, but are lim-
ited by the incomplete analysis of hemostasis they
generate, the relative big volume of donor blood required
and the low throughput [43]. Promising results have been
obtained with microfluidic devices demonstrating the abil-
ity to obtain a large number of data points per single pa-
tient sample using small blood volumes and high
throughput approach [44]. Although none of these flow-
based assays were available for the current work, a future
study should address the effect of periodontal therapy on
platelet functions under flow conditions.
One limitation of the current study is the absence of
an untreated (control) group. This would consist of peri-
odontitis patients left untreated for the whole duration
of the study. However, the inclusion of such a group is
unethical, and would be met with strong opposition by
the University Ethical Board. Furthermore, such a control
group has been shown to be susceptible to a high dropout
rate by patients who seek periodontal therapy elsewhere
[45]. Nevertheless, on the basis of the current study it is
not possible to establish whether the improvement in
platelet reactivity is solely related to the professionally-
applied periodontal therapy. It cannot be excluded that
some patients have changed their lifestyle after receiving
information about the negative effects of smoking, over-
weight, lack of physical activity or unhealthy diet. The
study protocol did not include the assessment of changes
in physical activity or diet, which might have been of influ-
ence on the measured platelet functions. The LDL levels
were lower post-treatment and, by the time of the recall
(3 months post-periodontal therapy), six out of the 14
smokers in the current study had quitted smoking. As
both LDL and smoking could influence platelet function
[46–48], we sought of estimating their effect on the mea-
sured platelet parameters by regression analysis. When ex-
ploring the predictive value of smoking or the changes in
LDL, systolic blood pressure, waist circumference for the
measured platelet parameters, no significant effect of these
variables was found. However, the study cohort is rather
limited, so this conclusion might be underpowered.
In conclusion, our results support the notion of a longi-
tudinal beneficial effect of periodontitis treatment on plate-
let function. Our results are a promising step towards an
increased awareness of the medical community for peri-
odontal therapy as a non-pharmacological intervention for
improving platelet function, and given the high prevalence
of periodontitis, could potentially benefit a large proportion
of the adult population.Conclusion
In conclusion, we suggest that periodontal therapy as an
intervention for improved oral health is one of the emer-
ging factors, in addition to lifestyle changes (nutrition,
physical activity and psychological wellbeing) contributing
to a reduction of the intrinsic platelet hyper-reactivity,
which on the long term can have substantial benefits in
preventing major cardiovascular events.
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